Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFusion Antibodies Regulatory News (FAB)

Share Price Information for Fusion Antibodies (FAB)

Share Price is delayed by 15 minutes
Get Live Data
13.00    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 1.00 (8.00%)
Market Cap: £16.25m
FAB Live PriceLast checked at - London Stock Exchange

Intraday Fusion Antibodies Share Chart

Acquisition

14 Jun 2007 07:01

Fabian Romania Property Fund Ltd14 June 2007 Fabian Romania Property Fund Limited ("Fabian Romania" or the "Fund") Fabian Romania announces the acquisition of an €8.0 million office developmentscheme in Bucharest Fabian Romania has signed a turn-key agreement with Hil Construct to purchaseits sixth office project in central Bucharest for a prospective purchase yieldof 8.9 per cent.. Completion is conditional on the attainment of the finalbuilding permit which is currently expected at the end of August 2007. The Romana office building will be built for the Fund on a centrally locatedsite on Dacia Boulevard. The building will be built to Class A specificationswith a gross area of approximately 3,000 square metres ("sqm"). The projectmanagement will be undertaken by Globus, an experienced local developer inRomania. Construction is due to commence in the fourth quarter 2007 withcompletion anticipated in the third quarter of 2009. Total construction costsare estimated to be in the order of €8.0 million. Upon completion, the building will provide a net lettable office area of around2,480 sqm over 7 floors, together with 40 car parking spaces. The building is ina prominent position with views over Plaza Romana and is likely to attractinternational tenants seeking Class A office space. Vacancy rates for Class Aoffice space in in Bucharest are less than 3 per cent.. The Fund, advised by itsinvestment manager Fabian Capital Limited ("Fabian Capital"), will assume theletting responsibility for the building. The estimated rental value of thebuilding upon completion is €715,000 per annum giving a prospective purchaseyield of 8.9 per cent.. Upon completion the Fund will pay the purchase price of €7.6 million to Hil in 3instalments; a first instalment of €2.0 million will be made for the company toacquire ownership of the land; a second instalment for construction costs ofapproximately €3.0 million; and a final payment upon practical completion of€2.6 million in the form of a bank guarantee. Including non developer relatedcosts, the total purchase price is forecast to be €8.0 million. The Fund'sequity requirement is expected to be €2 million with debt finance to fund thebalance. Dacia Boulevard is in the heart of Bucharest running between Calle Victoria andRomana Square. It is some 5 minutes by car from the Intercontinental Hotel. Thisarea is a popular office location. A number of international companies havetheir headquarters nearby. Commenting on the transaction, Mark Owen, Property Director of Fabian Capital,said: "We are pleased the Fund has signed another high quality office purchase shortlyafter the announcement of its intention to purchase the Evocenter. This newdevelopment is located in one of the most central positions you could hope toachieve in Bucharest and we are confident the Fund will achieve pre lets priorto completion. The building is flexible to provide sub 1,000 sqm floor plates ofwhich there is an under supply in the market whilst still otherwise providingClass A technical specifications. This investment will make it the third in thecentral core area of Bucharest for the Funds' expanding Portfolio." The lead advisers on the transaction were DTZ (property agent), WSP (technicaladvisers) and Tuca (legal adviser). For Comments:Fabian Romania:Mark Holdsworth +44 20 7499 9988 Nominated Adviser:Deloitte & Touche LLPJames Lewis +44 20 7936 3000 Broker:Shore Capital Stockbrokers LimitedDru Danford +44 20 7408 4090 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
2nd Jun 20267:00 amRNSExercise of options and total voting rights
11th May 20263:06 pmRNSHolding(s) in Company
11th May 202611:05 amRNSGrant of patent in Japan
5th May 20267:00 amRNSYear-end trading statement
30th Mar 20267:00 amRNSAntibody IP transfer agreement
17th Feb 202611:42 amRNSDirector/PDMR Shareholding
4th Feb 20263:27 pmRNSHolding(s) in Company
2nd Feb 202611:33 amRNSHolding(s) in Company
30th Jan 20265:00 pmRNSTotal Voting Rights
27th Jan 20267:05 amRNSIssue of Director Shares
27th Jan 20267:00 amRNSPlacing and Subscription to raise approx £1.4m
19th Dec 20257:00 amRNSUpdate on negotiations with NCI regarding OptiMAL
19th Dec 20257:00 amRNSUpdate on negotiations with NCI regarding OptiMAL
16th Dec 202511:04 amRNSLaunch of OptiMAL platform
11th Dec 20257:00 amRNS-RMammalian Display video
25th Nov 202512:11 pmRNSHolding(s) in Company
24th Nov 20257:00 amRNSHalf-year Financial Report
21st Nov 20257:00 amRNSNotice of Results
13th Nov 20257:00 amRNS-ROptiMAL Library video
3rd Nov 20257:00 amRNSOptiMAL® R&D Update
27th Oct 20253:38 pmRNSHolding(s) in Company
16th Oct 20251:31 pmRNSResult of AGM
16th Oct 20257:00 amRNSAGM statement and H1 trading update
8th Oct 20257:00 amRNSContract win
19th Sep 202512:58 pmRNSPosting of Annual Report & Notice of AGM
17th Sep 20257:00 amRNSOptiMAL R&D Update
8th Sep 20257:00 amRNS-RBelfast investor presentation
4th Sep 20257:00 amRNSFinal Results
28th Aug 20257:00 amRNSContract Win
27th Aug 20257:00 amRNSContract wins with existing client
26th Aug 20257:00 amRNS-RInvestor presentations
5th Aug 20257:00 amRNSGrant of U.S. Patent for OptiMAL
24th Jul 202510:56 amRNSIssue Notification: US Patent Update
11th Jul 20257:00 amRNSDirector/PDMR Shareholding
2nd Jun 20257:00 amRNSTotal Voting Rights
22nd May 20252:33 pmRNSUpdate on U.S. Patent for OptiMAL®
8th May 20257:00 amRNS-RInvestor presentation
7th May 20257:00 amRNSIssue of shares to non-executive directors
6th May 202510:53 amRNSDirector/PDMR Shareholding
6th May 202510:38 amRNSHolding(s) in Company
6th May 20257:00 amRNSTrading update
30th Apr 20255:00 pmRNSTotal Voting Rights
24th Apr 20257:00 amRNSApproval of grant funding
11th Apr 202510:40 amRNSHolding(s) in Company
10th Apr 202512:47 pmRNSHolding(s) in Company
7th Apr 202512:35 pmRNSResult of General Meeting
31st Mar 20255:00 pmRNSTotal Voting Rights
24th Mar 20254:38 pmRNSHolding(s) in Company
18th Mar 20257:00 amRNSPlacing to raise approximately £1.17 million
27th Feb 20257:00 amRNSContract win

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.